Table 1.
Baseline Clinical Characteristics of Study Patients
| All Patients | Trimetazidine | Placebo | |
| Mean age (years) | 65.4 ± 6.3 | 65.6 ± 5.7 | 65.2 ± 7 |
| Male | 24 | 11 | 13 |
| Female | 8 | 5 | 3 |
| BMI | 25.4 ± 3.2 | 25.7 ± 3.3 | 25.2 ± 3.3 |
| Baseline glucose | 164.6 ± 26.2 | 166.9 ± 21.9 | 162.2 ± 30.4 |
| Triglycerides at baseline | 238.1 ± 59.5 | 231.3 ± 43.7 | 244.9 ± 72.9 |
| Triglycerides at randomisation | 185.7 ± 46.4 | 180.5 ± 34 | 191 ± 57 |
| Cholesterol at baseline | 264.5 ± 27.8 | 263.3 ± 29.3 | 265.2 ± 27.2 |
| Cholesterol at randomisation | 198.3 ± 20.8 | 197.8 ± 21.9 | 198.8 ± 20.4 |
| HBA1c | 7.6 ± 0.8 | 7.7 ± 1 | 7.5 ± 0.6 |
| Prior MI | 18 | 9 | 9 |
| Prior CABG | 7 | 4 | 3 |
| Prior PTCA | 12 | 6 | 8 |
| Carotid Atherosclerosis | 12 | 7 | 5 |
| Coronary atherosclerosis | |||
| 1 vessel disease | 1 | 0 | 1 |
| 2 vessel disease | 14 | 6 | 8 |
| 3 vessel disease | 16 | 9 | 7 |
| any vessel + graft | 1 | 1 | 0 |
| distal disease | 23 | 12 | 11 |
| USE OF DRUGS AT RANDOMISATION | |||
| Aspirin/ticlopidine | 18 | 12 | 14 |
| Clopidogrel | 6 | 6 | 4 |
| Anticoagulants | 6 | 5 | 6 |
| Digitalis | 28 | 13 | 15 |
| Diuretics | 31 | 16 | 15 |
| Nitrates | 18 | 8 | 10 |
| B-blockers | 23 | 11 | 12 |
| Ca-antagonists | 14 | 9 | 6 |
| ACE-I | 29 | 14 | 15 |
| ARB | 4 | 2 | 2 |
| Statins | 30 | 14 | 16 |
| Oral hypoglycaemics | 25 | 12 | 13 |
| Insulin | 7 | 4 | 3 |
Clinical features of study patients. Clinical characteristics, incidence of previous myocardial infarction or revascularization procedures in patients randomized to trimetazidine or placebo. No significant differences were detected between groups. BMI = body mass index, MI = myocardial infarction, CABG = coronary artery by-pass grafting, PC I = percutaneous coronary interventions.